193153-04-7 Usage
Uses
Used in Pharmaceutical Industry:
Methyl (2R,3R)-2-[3-amidinobenzyl]-3-[[4-(1-oxido-4-pyridinyl)benzoyl]amino]butanoate is used as a potent and selective inhibitor of factor Xa (fXa) for the treatment of acute coronary syndrome. It exhibits a high affinity for fXa (Ki = 0.5 nM) and effectively inhibits both free and prothrombinase-bound fXa. Clinical studies have demonstrated its efficacy, safety, and tolerability in humans, making it a promising candidate for the development of new antithrombotic therapies.
Used in Drug Development:
Methyl (2R,3R)-2-[3-amidinobenzyl]-3-[[4-(1-oxido-4-pyridinyl)benzoyl]amino]butanoate can be utilized in the development of new drugs targeting various diseases and conditions. Its unique molecular structure and interactions with biological systems make it a valuable starting point for the design and synthesis of novel therapeutic agents. Researchers can use Methyl (2R,3R)-2-[3-amidinobenzyl]-3-[[4-(1-oxido-4-pyridinyl)benzoyl]amino]butanoate as a template to create new molecules with improved potency, selectivity, and pharmacokinetic properties.
Used in Medicinal Chemistry Research:
Methyl (2R,3R)-2-[3-amidinobenzyl]-3-[[4-(1-oxido-4-pyridinyl)benzoyl]amino]butanoate serves as an important tool in medicinal chemistry research. It can be used to study the structure-activity relationships of fXa inhibitors and other biologically active molecules. This knowledge can help researchers understand the molecular mechanisms underlying the compound's therapeutic effects and guide the development of more effective and safer drugs.
Check Digit Verification of cas no
The CAS Registry Mumber 193153-04-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,3,1,5 and 3 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 193153-04:
(8*1)+(7*9)+(6*3)+(5*1)+(4*5)+(3*3)+(2*0)+(1*4)=127
127 % 10 = 7
So 193153-04-7 is a valid CAS Registry Number.
193153-04-7Relevant articles and documents
Otamixaban for treatment of elderly and renal impaired non-ST elevation myocardial infarction patients
-
, (2016/12/07)
The invention relates to the use of (2R,3R)-2-(3-carbamimidoyl-benzyl)-3-[4-(1-oxy-pyridin-4-yl)benzoylamino]-butyric acid methyl ester or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in non-ST elevation myocardial infarction, said treatment comprising administering a therapeutically effective amount of (2R,3R)-2-(3-Carbamimidoyl-benzyl)-3-[4-(1-oxy-pyridin-4-yl)benzoylamino]-butyric acid methyl ester or a pharmaceutically acceptable salt thereof to a human patient, who is elderly and/or shows renal insufficiency and/or has a low body weight.
Novel crystalline forms of a factor Xa inhibitor
-
Page 11, (2010/02/05)
The present invention relates to novel crystalline forms of an inhibitor of Factor Xa, processes for its preparation, compositions comprising it, and its therapeutic use.
